Scholarlink

Purpose <p>To evaluate the efficacy of integrating <i>en bloc</i> resection, endoscopic submucosal dissection (ESD), and submucosal injection of chemotherapeutic agents with TURBT (cESD-TURBT).</p> Methods <p>This retrospective observational study&#xa0;was conducted on&#xa0;patients diagnosed with stage cTa–T1 bladder cancer&#xa0;who&#xa0;received TURBT&#xa0;between&#xa0;December 2020&#xa0;and&#xa0;July 2023 at Liaoning Cancer Hospital. The participants were grouped&#xa0;on the basis of the type of treatment they received: cESD-TURBT (<i>n</i> = 118) or conventional TURBT (cTURBT, <i>n</i> = 105). Hydroxycothecin&#xa0;is&#xa0;the chemotherapeutic agent used for submucosal injections. The primary outcome was the recurrence-free survival (RFS) of the treated patients with bladder cancer. The secondary outcomes included disease recurrence within one year, operation duration, length of postoperative hospitalization, and complication rates. Statistical analyses were performed via appropriate tests, with a threshold of <i>P</i> &lt; 0.05 defined as statistically significant.</p> Results <p>Compared with the cTURBT cohort, the cESD-TURBT cohort demonstrated increased RFS<b>,</b> with a median follow-up of 775&#xa0;days (interquartile range [IQR] 414–1040). The recurrence rate in the cESD-TURBT cohort was 18.6% (22/118), whereas it was 39.1% (41/105) in the cTURBT cohort, with a log-rank hazard ratio of 0.49 (95% CI 0.29–0.82; <i>p</i> = 0.0053). Furthermore, cESD-TURBT resulted in fewer postoperative complications than did cTURBT, markedly reducing the occurrence of complications, such as&#xa0;the obturator reflex (1.7% vs. 8.6%, <i>p</i> = 0.03). The difference in operation time was not statistically significant, with a cESD-TURBT of 49.0 ± 21.0&#xa0;min and a cTURBT of 44.3 ± 23.8&#xa0;min (<i>p</i> = 0.127).</p> Conclusion <p>Our analysis revealed that, compared with cTURBT, cESD-TURBT significantly lowers recurrence rates and is associated with fewer postoperative complications. Our study revealed that cESD-TURBT <b>is</b> superior to cTURBT for bladder tumor removal.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chemotherapy-enhanced endoscopic submucosal En Bloc dissection vs. conventional TURBT for NMIBC: a comparative study

  • 期刊论文

  • 发表日期：

    2025年3月9日

查看全文
  • Xi Liu,
  • Yiding Wang,
  • Zhe Wang,
  • Bo Shao,
  • Qiang Liu,
  • Changqi Li,
  • Chengcheng Lv,
  • Huan Bi,
  • Guangyi Shan,
  • Shui Fu,
  • Ang Chen,
  • Yu Zeng

摘要

Purpose

To evaluate the efficacy of integrating en bloc resection, endoscopic submucosal dissection (ESD), and submucosal injection of chemotherapeutic agents with TURBT (cESD-TURBT).

Methods

This retrospective observational study was conducted on patients diagnosed with stage cTa–T1 bladder cancer who received TURBT between December 2020 and July 2023 at Liaoning Cancer Hospital. The participants were grouped on the basis of the type of treatment they received: cESD-TURBT (n = 118) or conventional TURBT (cTURBT, n = 105). Hydroxycothecin is the chemotherapeutic agent used for submucosal injections. The primary outcome was the recurrence-free survival (RFS) of the treated patients with bladder cancer. The secondary outcomes included disease recurrence within one year, operation duration, length of postoperative hospitalization, and complication rates. Statistical analyses were performed via appropriate tests, with a threshold of P < 0.05 defined as statistically significant.

Results

Compared with the cTURBT cohort, the cESD-TURBT cohort demonstrated increased RFS, with a median follow-up of 775 days (interquartile range [IQR] 414–1040). The recurrence rate in the cESD-TURBT cohort was 18.6% (22/118), whereas it was 39.1% (41/105) in the cTURBT cohort, with a log-rank hazard ratio of 0.49 (95% CI 0.29–0.82; p = 0.0053). Furthermore, cESD-TURBT resulted in fewer postoperative complications than did cTURBT, markedly reducing the occurrence of complications, such as the obturator reflex (1.7% vs. 8.6%, p = 0.03). The difference in operation time was not statistically significant, with a cESD-TURBT of 49.0 ± 21.0 min and a cTURBT of 44.3 ± 23.8 min (p = 0.127).

Conclusion

Our analysis revealed that, compared with cTURBT, cESD-TURBT significantly lowers recurrence rates and is associated with fewer postoperative complications. Our study revealed that cESD-TURBT is superior to cTURBT for bladder tumor removal.